SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Angiodynamics Inc – ‘10-Q’ for 8/31/15 – ‘R8’

On:  Thursday, 10/8/15, at 4:36pm ET   ·   For:  8/31/15   ·   Accession #:  1275187-15-22   ·   File #:  0-50761

Previous ‘10-Q’:  ‘10-Q’ on 4/9/15 for 2/28/15   ·   Next:  ‘10-Q’ on 1/8/16 for 11/30/15   ·   Latest:  ‘10-Q’ on 4/9/24 for 2/29/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

10/08/15  Angiodynamics Inc                 10-Q        8/31/15   69:5.1M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    371K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
46: R1          Document and Entity Information                     HTML     41K 
36: R2          Consolidated Statements of Income                   HTML     89K 
44: R3          Consolidated Statements of Comprehensive Income     HTML     50K 
48: R4          Consolidated Balance Sheets                         HTML    127K 
63: R5          Consolidated Balance Sheets (Parenthetical)         HTML     47K 
38: R6          Consolidated Statements of Cash Flows               HTML    103K 
43: R7          Consolidated Statement of Stockholders' Equity      HTML     70K 
32: R8          Consolidated Financial Statements                   HTML     30K 
25: R9          Inventories                                         HTML     32K 
64: R10         Goodwill and Intangible Assets                      HTML     75K 
50: R11         Accrued Liabilities                                 HTML     38K 
49: R12         Long Term Debt                                      HTML     30K 
54: R13         Income Taxes                                        HTML     59K 
55: R14         Share-Based Compensation                            HTML     30K 
53: R15         Earnings Per Share                                  HTML     33K 
56: R16         Segment and Geographic Information                  HTML     49K 
45: R17         Fair Value                                          HTML    138K 
47: R18         Marketable Securities                               HTML     53K 
52: R19         Commitments and Contingencies                       HTML     35K 
69: R20         Recently Issued Accounting Pronouncements           HTML     32K 
59: R21         Restructuring                                       HTML     24K 
40: R22         Inventories (Tables)                                HTML     31K 
51: R23         Goodwill and Intangible Assets (Tables)             HTML     70K 
42: R24         Accrued Liabilities (Tables)                        HTML     37K 
19: R25         Income Taxes (Tables)                               HTML     54K 
60: R26         Earnings Per Share (Tables)                         HTML     31K 
65: R27         Segment and Geographic Information (Tables)         HTML     44K 
28: R28         Fair Value (Tables)                                 HTML    131K 
27: R29         Marketable Securities (Tables)                      HTML     46K 
30: R30         Consolidated Financial Statements - Additional      HTML     70K 
                Information (Detail)                                             
31: R31         Acquisitions - Additional Information (Detail)      HTML     36K 
33: R32         Inventories - Schedule of Inventories (Detail)      HTML     30K 
18: R33         Goodwill and Intangible Assets - Additional         HTML     25K 
                Information (Detail)                                             
57: R34         Goodwill and Intangible Assets - Goodwill by        HTML     22K 
                Segment (Detail)                                                 
39: R35         Goodwill and Intangible Assets - Intangible Assets  HTML     57K 
                (Detail)                                                         
41: R36         Accrued Liabilities - Summary of Accrued            HTML     52K 
                Liabilities (Detail)                                             
22: R37         Long Term Debt - Additional Information (Detail)    HTML     77K 
68: R38         Income Taxes - Components of Income Tax             HTML     40K 
                Expense/(Benefit) (Detail)                                       
12: R39         Income Taxes - Additional Information (Detail)      HTML     31K 
34: R40         Income Taxes Net Operating Loss Carryforwards       HTML     45K 
                (Details)                                                        
62: R41         Share-Based Compensation (Details)                  HTML     29K 
21: R42         Earnings Per Share - Reconciliation of Basic to     HTML     28K 
                Diluted Weighted-Average Shares Outstanding                      
                (Detail)                                                         
26: R43         Segment and Geographic Information - Additional     HTML     22K 
                Information (Detail)                                             
29: R44         Segment and Geographic Information - Summary of     HTML     31K 
                Net Sales by Product Category (Detail)                           
37: R45         Segment and Geographic Information - Summary of     HTML     31K 
                Net Sales by Geographic Area (Detail)                            
17: R46         Fair Value - Additional Information (Detail)        HTML     21K 
24: R47         Fair Value - Fair Value of Assets and Liabilities   HTML     67K 
                Measured on a Recurring Basis (Detail)                           
14: R48         Fair Value - Fair Value Measurements Using          HTML     41K 
                Significant Unobservable Inputs (Detail)                         
61: R49         Fair Value - Summary Showing the Recurring Fair     HTML     53K 
                Value Measurements of the Contingent Consideration               
                Liability (Detail)                                               
20: R50         Fair Value - Summary Showing Reconciliation of the  HTML     25K 
                Contingent Payments (Detail)                                     
58: R51         Marketable Securities - Additional Information      HTML     23K 
                (Detail)                                                         
23: R52         Marketable Securities - Marketable Securities       HTML     34K 
                (Detail)                                                         
35: R53         Commitments and Continfencies - Additional          HTML     35K 
                Information (Detail)                                             
13: R54         Restructuring - Additional Information (Detail)     HTML     26K 
16: R55         Immaterial Corrections (Details)                    HTML    111K 
67: XML         IDEA XML File -- Filing Summary                      XML    120K 
15: EXCEL       IDEA Workbook of Financial Reports                  XLSX     63K 
 6: EX-101.INS  XBRL Instance -- ango-20150831                       XML   1.26M 
 8: EX-101.CAL  XBRL Calculations -- ango-20150831_cal               XML    187K 
 9: EX-101.DEF  XBRL Definitions -- ango-20150831_def                XML    507K 
10: EX-101.LAB  XBRL Labels -- ango-20150831_lab                     XML   1.25M 
11: EX-101.PRE  XBRL Presentations -- ango-20150831_pre              XML    786K 
 7: EX-101.SCH  XBRL Schema -- ango-20150831                         XSD    144K 
66: ZIP         XBRL Zipped Folder -- 0001275187-15-000022-xbrl      Zip    167K

‘R8’   —   Consolidated Financial Statements

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v3.3.0.814
Consolidated Financial Statements
 3 Months Ended
Accounting Policies [Abstract]  
Consolidated Financial Statements
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
The consolidated condensed balance sheet as of August 31, 2015, the consolidated condensed statement of stockholders’ equity for the three months ended August 31, 2015 and consolidated condensed statement of cash flows, the consolidated condensed statements of income (loss) and the consolidated condensed statements of comprehensive income (loss) for the three months ended August 31, 2015 and 2014 have been prepared by us without audit. The consolidated condensed balance sheet as of May 31, 2015 was derived from audited consolidated condensed financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2015 (and for all periods presented) have been made.
The unaudited interim consolidated condensed financial statements for the three months ended August 31, 2015 and August 31, 2014 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
We have reclassified certain amounts in prior period financial statements to conform to the current period's presentation.

Recent Developments

EmboMedics, Inc. - on March 2, 2015, the Company filed a current report on form 8-K stating that it executed a non-binding letter of intent to enter into a strategic relationship with privately-held EmboMedics Inc., which develops injectable and resorbable embolic microspheres. On April 9, 2015 the Company entered into a License, Distribution, Manufacturing and Purchase Option Agreement with EmboMedics Inc., subject to certain approvals by EmboMedics shareholders.

Under the terms of the agreement, which has not been finalized, AngioDynamics receives an exclusive worldwide license to market and sell, upon regulatory clearances, EmboMedics’ microsphere technology. AngioDynamics will also control manufacturing of the products. Final terms of the agreement, including the form and amount of payments, have not yet been finalized, but the Company expects the terms to include a combination of milestone payments and equity investments, up to and including an option to acquire EmboMedics.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:10/8/158-K
For Period end:8/31/15
5/31/1510-K
4/9/1510-Q,  8-K
3/2/158-K
8/31/1410-Q,  NT 10-Q
 List all Filings 
↑Top
Filing Submission 0001275187-15-000022   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 17, 2:01:38.1pm ET